Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
4basebio Plc LSE:4BB London Ordinary Share GB00BMCLYF79 ORD EUR1.00
  Price Change % Change Share Price Shares Traded Last Trade
  -5.00 -0.67% 740.00 802 08:00:28
Bid Price Offer Price High Price Low Price Open Price
730.00 750.00 747.50 740.00 740.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.34 -3.64 -26.00 91
Last Trade Time Trade Type Trade Size Trade Price Currency
14:00:03 UT 2 745.00 GBX

4basebio (4BB) Latest News

More 4basebio News
4basebio Investors    4basebio Takeover Rumours

4basebio (4BB) Discussions and Chat

4basebio Forums and Chat

Date Time Title Posts
30/9/202207:404BaseBio - Innovation in Gene Synthesis and Delivery84
21/2/202120:074BaseBio14

Add a New Thread

4basebio (4BB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-02-03 14:00:03745.00214.90UT
2023-02-03 10:53:36730.008005,840.00O
View all 4basebio trades in real-time

4basebio (4BB) Top Chat Posts

Top Posts
Posted at 03/2/2023 08:20 by 4basebio Daily Update
4basebio Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker 4BB. The last closing price for 4basebio was 745p.
4basebio Plc has a 4 week average price of 685p and a 12 week average price of 655p.
The 1 year high share price is 750p while the 1 year low share price is currently 400p.
There are currently 12,317,473 shares in issue and the average daily traded volume is 4,650 shares. The market capitalisation of 4basebio Plc is £91,149,300.20.
Posted at 30/9/2022 06:40 by pob69
Finncap comment;

...results reflect consistent progress towards its main objective of producing GMP-grade synthetic DNA, while at the same time it is building incremental value into the business through product/technology expansion with first commercial sales of its DNA and increasing corporate partnerships. It generated revenues of £0.15m with adjusted pre-tax loss of £2.7m (H1 2021: £1.8m, +45%) and ended the period with £5.6m cash. Despite the expected increase in cashburn as headcount increases, near-term funding is not considered an issue, given that it can draw down from its €25m loan facility.

...minor changes to forecasts to reflect increased headcount and higher capex, with year-end cash forecast to be £1.9m (previously £2.3m). We maintain our sum-of-the-parts DCF target price of 1,200p, which is underpinned by the expected high demand for DNA/RNA and the significant potential of its technology to address key challenges in the cell and gene therapy space.

Posted at 25/7/2022 15:34 by buzzzzzzzz
Nice to see the CFO pick up another 5,000 shares in June.

Management certainly putting their money where their mouth is!

Decent buying today pushing price back up.

Posted at 15/2/2022 11:02 by buzzzzzzzz
Great runs today
Production will start on schedule and with first commercial order.
A real coup nicking cooper from ABCAM he must have faith in 4BB.

Posted at 30/9/2021 17:37 by buzzzzzzzz
Touchlight (synthetic DNA manufacturer
with FY 2020 sales of £10.6m) recently extended its private financing round to $125m, and while
we do not have visibility on the pre-money valuation, we estimate it is in excess of $500m.

It will take some time for 4basebio to build up its customer base, and so it is unlikely that it will be able
to generate significant revenues in the early stages of GMP DNA production. However, its new facility
will provide it with both huge manufacturing flexbility and very large DNA production capacity.
The cell and gene therapy space is undergoing accelerated expansion – in January 2019, the FDA
announced that from 2020, it anticipated that it would receive more than 200 CGT investigational
new drug (IND) applications per year, in addition to the 800 active cell-based or gene therapy INDs
that it already had on file at the time. The cell and gene therapy catapult UK preclinical research
database identified 875 project in 2018, compared with 720 in 2017 (a growth of 20%, and a number
which has undoubtedly grown since). These developers and their growing pre-clinical and clinical
product ranges will all require DNA, and they represent an enormous customer pool that 4basebio
can tap into, which presents it with a ‘land grab’ opportunity, in our view.
If 4basebio can build relationships with these parties now, while most cell and gene therapies are
in the pre-clinical stage of development, it can secure a very stable base of recurring revenue – once
a company incorporates 4basebio’s DNA into its construct, it will likely use the DNA throughout the
entire clinical trial stage and beyond.


This model of ‘sticky’ recurring revenues is similar to that of Maxcyte (AIM: MXCT), which pioneered
the development of a non-viral cell- engineering platform – Flow Electroporation┬«. MaxCyte
provides its technology, including instruments and single-use disposables, to customers to aid in
drug discovery and development. It also licenses the technology to companies that can use it to
reprogramme cells to be used as therapies, for which MaxCyte receives upfront and milestone
payments, as well as royalties on future product sales. MaxCyte now has a market cap of c.£1bn
(Figure 5) and trades on FY 2021 and FY 2022 EV/Sales of 36x and 28x, respectively.


These valuations are not out of reach of 4BB.

There is no reason why 4BB cannot reach £25m revenue which could push the valuation to that of Touchlight.

Posted at 29/9/2021 06:20 by buzzzzzzzz
Not that anyone will have noticed the RNS yesterday judging from reaction on the BB

For me the killer info is


"In order to develop the manufacturing
capacity required, 4basebio UK, a subsidiary of the Company, has secured a long
term lease for the Facility".

It certainly seems to me that the Company are anticipating large demand for DNA.

Potential revenue of £25m/annum

Current share price too low IMHO

Posted at 22/8/2021 17:13 by buzzzzzzzz
Not that anyone will have noticed but Kurt Zoors has increased his stake in 2Invest AG, which owns 30% of 4BB from 46% to 51.77%

A cheap way to aquire 4BB is to buy 2Invest shares as they are trading below the cash value of the share.

Each share of of 2Invest is has an interest in 0.65 of a 4BB share approx.

So 2Invest shares are trading below the cash value never mind 0.65 x £6.50 = £4.220

Call it 4.5 euro's to be conservative.

There is only one way this share is headed.

Posted at 09/8/2021 10:00 by buzzzzzzzz
Nice to see a little volume today.

Consolidation at this level would be nice to see.

Interestingly the 2invest share price has risen to 13.30 euro's.

So one can buy an inerest in 4BB by buying their shares as 2Invest own 30% of 4BB.


Probably talking to myself!

Posted at 02/8/2021 06:35 by buzzzzzzzz
Loving the share price rise on very small volume.

Shares obviosly very tightly held, mine are!!!

Calling share price £10.00 by Christmas

Posted at 16/3/2021 18:11 by zurg the indestructible
Multibagger

If the company increased liquidity by raising cash that is not needed it would undoubtedly be by Institutions and not necessarily result in more shares in circulation.

as for your ascertation that the share price would be 3x or 4x higher, so what, all it would mean is that the share price has got ahead of itself.

What this share needs is news which results in the price rising and tempting holders to sell. The majority of the free float is in German hands and I don't think it would take too much of a rise to tempt them to sell.

I am sorry to dissappoint you but I am not a director or management or even an employee but just a shareholder from the initial start up in 2003 and I only have a small holding.

I do not understand what you mean by a re run of the Frankfurt listing, that was a merger with Sygnis which was already on the Frankfurt market and there was plenty of liquidity there.

If you think the share price should be 3x then why are you not slowly accumulating at these levels?

Posted at 16/3/2021 15:41 by multibagger
I gather a Finncap broker note has been released which may explain a bit of life in the share today. 4BB company is in the right space and at the right time, market sentiment for cutting edge biotech is red hot.

However, the lack of liquidity is asphyxiating this share and BoD don't seem to get this. If liquidity issues are ironed out on the UK market, through raising funds (even though funds may not be immediately necessary), then paradoxically I see this trading at 4x or 5x, the share price we are at now.

So one of those rare instances when equity dilution and fund raising will actually benefit the share price, contrary to what the BOD think. Time for the major share holders on the BoD to relax and not try to hold on far too tightly to their shares. It is counterproductive.

Contrarian thinking one could argue, but could be transformative to unleash the potential of this share. I am sure that the senior people of 4BB from a scientific background, are sharp enough to understand how markets work or how investors/traders think.

Or else this UK AIM listing will be a re-run of the Frankfurt all over again.....and then will they consider listing in Paris or Oslo I wonder ?

4basebio share price data is direct from the London Stock Exchange
Your Recent History
LSE
4BB
4basebio
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230204 06:54:08